Nitric oxide synthase inhibitors with cardiovascular therapeutic potential

Bibliography

• FURCHGOTT RF, ZAWADZKI JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 288:373–376.
   PubMed Web of Science ®Google Scholar
• PALMER RMJ, FERRIGE AG, MONCADA S: Nitric oxide re-lease accounts for the biological activity of endothe-IMm derived relaxing factor. Nature (1987) 327:524–526.
   PubMed Web of Science ®Google Scholar
• IGNARRO LJ, BUGA GM, WOOD KS, BYRNS RE, CHAUND-HURI G: Endothelium-derived relaxing factor pro-duced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA (1987) 84:9265–9269.
   PubMed Web of Science ®Google Scholar
• ••Historically important determination of NO as the EDRF.
   Google Scholar
• CHRISTOPHERSON KS, BREDT DS: Nitric oxide in excit- able tissues: physiological roles and diseases. J. Clin. Invest. (1997) 100(102424–2429.
   Google Scholar
• KERWIN JF, JR., LANCASTER JR, JR., FELDMAN PF: Nitric oxide: a new paradigm for second messengers. J. Med. Chem. (1995) 38(22):4343–4362.
   PubMed Web of Science ®Google Scholar
• MARLETTA MA: Approaches toward selective inhibition of nitric oxide synthase. J. Med. Chem. (1994) 37:1899–1907.
   PubMed Web of Science ®Google Scholar
• •Selective NOS inhibitors.
   Google Scholar
• KERWIN JF, HELLER M: The arginine-nitric oxide path-way: a target for new drugs. Med. Res. Rev. (1994) 14:23–74.
   PubMed Web of Science ®Google Scholar
• FOSTERMANN U, CLOSS El, POLLOCK JS: Nitric oxidesynthase isoenzymes. Characterization, purification, molecular cloning, and functions. Hypertension (1994) 23:1121–1131.
   Google Scholar
• WANG Y, MARSDEN PA: Nitric oxide synthases: genestructure and regulation. Adv. Pharmacol. (1995) 34:71–90.
   PubMedGoogle Scholar
• STUEHR DJ: Structure-function aspects in the nitric ox-ide synthases. Ann. Rev. Pharmacol. Toxicol. (1997) 37:339–59.
   PubMed Web of Science ®Google Scholar
• IGNARRO LJ: Biological actions and properties ofendothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. (1989) 65:1–21.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ, FULTON GJ, HAGEN P-0: Clinical biology of nitric oxide. Br. J. Surgery (1995) 82:1598–1610.
   PubMed Web of Science ®Google Scholar
• MICHEL T, FERON O: Nitric oxide synthases: which, where, how, and when. J. Clin. Invest. (1997) 100(9):2146–2152.
   PubMed Web of Science ®Google Scholar
• MICHEL T, XIE Q-W, NATHAN C: Molecular biological analysis of nitric oxide synthases. In: Methods in Nitric Oxide Research. Feelisch M, Stamler JS (Eds.), John Wiley & Sons, UK (1995):161–175.
   Google Scholar
• MARLETTA MA: Nitric oxide synthase structure and mechanism. J. Biol. Chem. (1993) 268:12231–12234.
   PubMed Web of Science ®Google Scholar
• NATHAN C: Inducible nitric oxide synthase: what dif-ference does it make?./. Clin. Invest. (1997) 100(10):2417–2423.
   Google Scholar
• •Interesting review of the physiological role of iNOS.
   Google Scholar
• CLANCY RM, AMIN AR, ABRAMSON SB: The role of nitric oxide in inflammation and immunity. Arthritis Rheum. (1998) 41:1141–1151.
   PubMed Web of Science ®Google Scholar
• MONCADA S, PALMER RMJ, HIGGS EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. (1991) 43 (2) :109–142.
   PubMedGoogle Scholar
• BASSENGE E: Coronary responses: role of endothelium and nitrovasodilators. Cardiovasc. Drugs Ther. (1994) 8 (4) :601–610.
   PubMedGoogle Scholar
• MCINTYRE M, DOMINICZAK AF: Nitric oxide and cardio-vascular disease. Postgrad. Med. J. (1997) 73(864) :630–634.
   PubMedGoogle Scholar
• •Concise review of the role of NO in cardiovascular disease with useful references.
   Google Scholar
• SCHULZ R, TRIGGLE CR: Role of NO in vascular smooth muscle and cardiac muscle function. Trends Pharmacol. Sci. (1994) 15:255–259.
   PubMed Web of Science ®Google Scholar
• NAKAKI T, HISHIKAWA K, SUZUKI H, SARUTA T, KATO R: t-Arginine induced hypotension. Lancet (1990) 336:696.
   PubMed Web of Science ®Google Scholar
• ARNAL FJ, EL-AMRANI Al, CHATELLIER G, MENARD J, MI-CHEL JB: Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension (1993) 22:380–387.
   PubMedGoogle Scholar
• HUANG PL, HUANG Z, MASHIMO H: Hypertension inmice lacking the gene for endothelial nitric oxide syn-thase. Nature (1995) 37:239–242.
   Google Scholar
• •Interesting article concerning eNOS knock-out mice.
   Google Scholar
• CANNON III RO: Role of nitric oxide in cardiovasculardisease: focus on the endothelium. Clin. Chem. (1998) 44(8B):1809–1819.
   Google Scholar
• HAYWOOD GA, TSAO PS, VON DER LEYEN HE et al: Ex-pression of inducible nitric oxide synthase in human heart failure. Circulation (1996) 93:1087–1094.
   PubMed Web of Science ®Google Scholar
• MACDONALD P, SCHYVENS C, WINLAW D: The role of nitric oxide in heart failure. Drugs Aging (1996) 8(6)452–458.
   Google Scholar
• NAVA E, PALMER RMJ, MONCADA, S: Inhibition of nitric oxide synthesis in septic shock. Lancet (1991) 338:1555–1557.
   PubMed Web of Science ®Google Scholar
• KILBOURN RG, GROSS SS, JUBRAN A et al.: NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involve-ment of nitric oxide. Proc. Natl. Acad. ScL USA (1990) 87:3629–3632.
   PubMed Web of Science ®Google Scholar
• PETROS A, LAMB G, LEONE A, MONCADA S, BENNETT D,VALLANCE P: Effects of a nitric oxide synthase inhibi-tor in humans with septic shock. Cardiovasc. Res. (1994) 28: 34–39.
   PubMed Web of Science ®Google Scholar
• •Significant account of a NOS inhibitor in human septic shock.
   Google Scholar
• MCMURRY J, ABDULLAH I, DARGIE H, SHAPIRO D: In-creased concentration of tumor necrosis factor in `cachectic' patents with severe chronic heart failure. Br. Heart J. (1991) 66:356–358.
   PubMedGoogle Scholar
• WINSLOW DS, SMYTHE GA, KEOGH AM et al.: Increased nitric oxide production in heart failure. Lancet (1994) 344:373–374.
   PubMedGoogle Scholar
• WINSLOW DS, SMYTHE GA, KEOGH AM et al.: Nitric ox-ide production and heart failure. Lancet (1995) 345:390–391.
   Google Scholar
• MANN D, YOUNG J: Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest. (1994) 105:897–904.
   PubMed Web of Science ®Google Scholar
• FINKEL MS, ODDIS CV, JACOB TD et al.: Negative ino-tropic effects of cytokines on the heart mediated by ni-tric oxide. Science (1992) 257(5068):387–389.
   PubMedGoogle Scholar
• USUI M, MATSUOKA H, MIYAZAKI H et al.: Increased en-dogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci. (1998) 62(26)2425–2430.
   Google Scholar
• BUISSON A, PLOTKINE M, BOULU RG: The neuroprotec-tive effect of a nitric oxide inhibitor in a rat model of focal cerebral ischemia. Br. J. PharmacoL (1992) 106:766–767.
   PubMed Web of Science ®Google Scholar
• IDAECOLA C, ZHANG F, XU X: Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am. J. Physiol (1995) 268–37:R286–R292.
   Google Scholar
• NISHIKANA T, KIRSCH JR, KOEHLER RC: N-Nitro-L-a-rginine methyl ester attenuates caudate injury during focal ischemia in cats. J. Cereb. Blood Flow Metab. (1994) 13:S154.
   Google Scholar
• STAGLIANO NE, DIETRICH WD, PRADO R, GREEN EJ, BUSTO R: The role of nitric oxide in the pathophysiol-ogy of thromboembolic stroke in the rat. Brain Res. (1997) 759:32–40.
   PubMedGoogle Scholar
• MORIKAWA E, HUANG Z, MOSKOWITZ MA: L-Argininedecreases infarct size caused by middle artery occlu-sion in spontaneously hypertensive rats. Am. J. Physic)]. (1992) 263:H1632–H1635.
   Google Scholar
• MORIKAWA E, ROSENBLATT S, MOSKOWITZ MA: L-A-rginine dilates rat pial arterioles by nitric oxide-dependent mechanisms and increases blood flow dur-ing focal cerebral ischemia. Br. J. Pharmacol (1992) 107:905–907.
   PubMed Web of Science ®Google Scholar
• ZHANG F, WHITE JG, IADECOLA C: Nitric oxide donorsincrease blood flow and reduce brain damage in focal ischemia: evidence that nitric oxide is beneficial in the early stages on cerebral ischemia. J. Cereb. Blood Flow Metab. (1994) 14:217–226.
   PubMed Web of Science ®Google Scholar
• STOCLET J-C, TRONCY E, MULLER B, BRUA C,KLESCHYOV AL: Molecular mechanisms underlying the role of nitric oxide in the cardiovascular system. Exp. Opin. Invest. Drugs (1998) 7(10:1769–1779.
   PubMedGoogle Scholar
• PITZELE BS: The modulation of the action of isoformsof nitric oxide synthase. Exp. Opin. Ther. Patents (1997) 7 (7):717–727.
   Web of Science ®Google Scholar
• PITZELE BS: The inhibition of isoforms of nitric oxidesynthase: non cardiovascular aspects. Exp. Opin. Ther. Patents (1999) 9(5):549–556.
   Web of Science ®Google Scholar
• Glaxo Wellcome has problems in sepsis. Scrip (1998)2330:21.
   Google Scholar